In an additional, 30-week placebo-controlled, study of patients with type 2 diabetes inadequately controlled with metformin comparing the maintenance of sitagliptin 100 mg versus withdrawal of sitagliptin when initiating basal insulin therapy, the event rate and incidence of documented symptomatic hypoglycemia (blood glucose measurement 70 mg/dL) did not differ between the sitagliptin and placebo groups
The absence of FDA-approved GLP-1 patches also increases the risk for unexpected side effects and adverse reactions
Basically, the risks are high and you should not do this yourself -- especially GH analogs
The Journal Of Nutrition, v
Lund-Andersen C, Patzke S, Nhse-Kumpf V, et al
Weight-loss injections are a pathway to a healthier lifestyle